<DOC>
	<DOCNO>NCT02960503</DOCNO>
	<brief_summary>Sickle cell anemia ( SCA ) life-threatening , monogenic disorder associate early death compare individual without SCA . Pulmonary complication , namely acute chest syndrome , obstructive lung disease pulmonary hypertension , common cause death patient SCA . Recent study suggest lung specific inflammation hallmark SCA underlies pulmonary pathology . To date , therapy show improve pulmonary complication SCA . Macrolides pleomorphic effect lung improvement pulmonary function , symptom inflammatory marker demonstrate several inflammatory pulmonary condition cystic fibrosis , asthma , COPD post-transplant bronchiolitis obliterans . Investigators hypothesize low dose macrolide therapy well tolerate improve pulmonary function symptom patient SCA . The objective project ass feasibility macrolides attenuate reverse decrease % predict FEV1 adult SCA single-site , randomize , placebo-controlled feasibility trial .</brief_summary>
	<brief_title>Macrolide Therapy Improve Forced Expiratory Volume 1 Second Adults With Sickle Cell Disease</brief_title>
	<detailed_description>Specific aim 1 : To determine acceptability clinical trial participant randomly allocate either placebo azithromycin 500 mg 3 day week 6 month adult SCD FEV1 &lt; 80 % . To assess acceptability intervention , investigator measurement recruitment rate , retention adherence study medication . Recruitment assess proportion eligible participant agree randomize . Retention measure proportion randomly allocate complete trial . Dropout due toxicity categorize use questionnaire . Medication adherence assess use previously validate 8 item modify Morisky medication adherence scale ( MMAS-8 ) , responses categorize : high adherence ( 8 point ) , average adherence ( 6-7 point ) , poor adherence ( 0-5 point ) . If recruitment rate &lt; 60 % , retention rate &lt; 80 % , average adherence rate ≤5 point , original protocol examine alternative strategy enhance recruitment , retention , adherence consider . Specific aim 2 : To evaluate effect 6 month low dose azithromycin therapy FEV1 respiratory symptom patient SCA . Baseline FEV1 test portable , in-office spirometer complete study enrollment end study period ( 6 month ) . The previously validate American Thoracic Society ( ATS-DLD-78 adult ) questionnaire also use evaluate respiratory symptom baseline end study . Under separate protocol , investigator calculate coefficient variation FEV1 % predict adult sickle cell disease order define within-subject variability test respiratory function specific population , previously describe within medical literature . Calculation coefficient variation FEV1 % predict essential interpretation clinically statistically meaningful change spirometry participant treat azithromycin improve baseline pulmonary function compare control .</detailed_description>
	<mesh_term>Anemia , Sickle Cell</mesh_term>
	<criteria>Inclusion criterion : 1 . Established diagnosis sickle cell disease ( HbSS , HbSC , HbS/β+ , HbS/β0 ) 2 . Age 1850 year 3 . FEV1 &lt; 80 % predict 4 . Willingness make return visit availability telephone duration study . Exclusion criterion : 1 . Acute respiratory symptom 2 . FEV1 &gt; 80 % 3 . Inability swallow pill 4 . Hypersensitivity macrolides . 5 . History cardiac arrhythmia 6 . Prolonged QTc interval ( &gt; 500 m ) baseline EKG 7 . Baseline impairment hearing pure tone audiometry define patient ageadjusted hear threshold &gt; 95th percentile one frequency 500 , 1000 , 2000 4000 Hz . 8 . The presence diagnosis SCD result patient medically unstable , predicted life expectancy le 1 year . 9 . Special patient group : prisoner , pregnant woman , institutionalized patient 10 . Women risk become pregnant study , refuse use acceptable mean birth control ( hormonal base oral , intrauterine device barrier contraception ) duration study . 11 . Patients take tacrolimus , pimozide , disopyramide , cyclosporine , nelfinavir , bromocriptine , hexobarbital . 12 . Patients take medication prolong QTc interval .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>November 2016</verification_date>
	<keyword>sickle cell disease</keyword>
	<keyword>pulmonary complication</keyword>
	<keyword>reduce FEV1</keyword>
	<keyword>azithromycin</keyword>
	<keyword>lung function</keyword>
</DOC>